Geneva Partners LLC Decreases Holdings in Eli Lilly and Company $LLY

Posted by Stanley Muller on Jul 8th, 2026

Eli Lilly and Company logo Geneva Partners LLC reduced its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 67.4% during the first quarter, according to its most recent filing with the SEC. The fund owned 5,119 shares of the company’s stock after selling 10,597 shares during the quarter. Eli Lilly and Company accounts for approximately 2.3% of Geneva Partners LLC’s portfolio, making the stock its 21st largest holding. Geneva Partners LLC’s holdings in Eli Lilly and Company were worth $4,708,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $25,000. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the last quarter. Basso Capital Management L.P. bought a new position in shares of Eli Lilly and Company during the 4th quarter worth $30,000. Finally, Maseco LLP increased its holdings in Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after acquiring an additional 28 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: JPMorgan raised its price target on Eli Lilly to $1,400 from $1,300 and reiterated an overweight rating, signaling continued upside expectations for the stock. Benzinga report on JPMorgan price target raise
Positive Sentiment: Shares hit a fresh 52-week high, reflecting momentum buying and strong investor enthusiasm around Lilly’s GLP-1 and obesity-treatment pipeline. CNBC report on Eli Lilly hitting 52-week high
Positive Sentiment: Weak results from Kailera Therapeutics’ weight-loss pill IPO appear to have indirectly helped Lilly by reinforcing the market’s confidence in Lilly’s lead position in obesity drugs. Yahoo Finance article on Kailera setback and Lilly market cap
Positive Sentiment: Commentary from Jim Cramer and other market-watch pieces remained constructive on biotech and Lilly’s growth story, suggesting investors still see the company as a core winner in the GLP-1 boom. 247WallSt Cramer commentary on Eli Lilly
Neutral Sentiment: Several articles highlighted Lilly as a top healthcare stock to own and as a long-term growth story, but these were mainly opinion pieces rather than new company-specific developments. Motley Fool article on Eli Lilly stock
Neutral Sentiment: Recent partnership and China-related business updates show Lilly is still actively managing its broader pipeline and regional strategy, but they appear less important than the obesity franchise news for today’s move. Yahoo Finance article on R&D collaboration and China rights transfer
Negative Sentiment: Some coverage continues to point to regulatory and pricing-policy risks for Lilly, which could weigh on sentiment over time even as the stock remains strong now. Yahoo Finance article on regulatory and pricing policy challenges

Analysts Set New Price Targets

Several analysts have recently issued reports on LLY shares. Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. HSBC cut Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price target for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,243.22.

View Our Latest Stock Analysis on LLY

Eli Lilly and Company Trading Up 2.8%

Shares of LLY opened at $1,233.32 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The firm has a 50 day moving average price of $1,078.08 and a 200-day moving average price of $1,030.27. The firm has a market cap of $1.16 trillion, a price-to-earnings ratio of 43.81, a PEG ratio of 1.49 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 35.74 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.